Axsome: AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.
Read full article »
Axsome is a New York-based biopharmaceutical company that researches and develops novel therapies for the treatment of central nervous system disorders.
Read more